medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2019, Number 5

<< Back Next >>

Rev Mex Oftalmol 2019; 93 (5)

Twelve-month outcomes of ranibizumab for diabetic macular edema in routine clinical practice in Mexico

Orozco-Gómez LP, Hernández-Salazar L, Flores-Peredo V, Ortega-Villalobos AL, Aranda-Serna S, Gerardo-Ferreyra L, Pérez-González E, Pérez-Monjaraz J, Ruiz-Franco AS

Language: Spanish
References: 17
Page: 238-245
PDF size: 232.51 Kb.


ABSTRACT

Purpose: To evaluate visual acuity (VA) and central retinal thickness (CRT) outcomes in patients treated with ranibizumab for diabetic macular edema (DME) in a clinical setting in Mexico. Methods: A prospective, open-label, single arm study was performed on 48 eyes of 34 patients with center-involving DME at four high-specialty ISSSTE hospitals in Mexico. Patients initially received a loading dose of 3 injections of ranibizumab, followed by monthly monitoring based on VA and CRT to determine retreatment need. VA, CRT, ETDRS diabetic retinopathy severity scale (DRSS) score, and number of injections were recorded at baseline and monthly for 12 months. Results: The mean VA, mean CRT, mean DRSS score at baseline were 19 (± 14) ETDRS letters, 362 (± 98) µm and 50.59 (± 7.9). The mean VA change at 12 months was +8.6 (± 4.3) letters (p ‹ 0.001) from baseline. The proportion of eyes that gained ≥ 10 letters was 38.58% (n = 19) and 37.50% (n = 18) gained ‹ 10 letters; 4.16% (n = 2) had no change, and 18.75% (n = 9) lost ‹‹ 10 letters. At month 12, mean CRT change was −85.34 (± 32.1) µm (‹ 0,001) and the DRSS score was 45.79 (± 7.9) (p ‹ 0.001). Patients received a mean of 6.7 (± 2.2) injections over 12 months. Conclusion: Patients showed visual and anatomical improvement after receiving ranibizumab in a clinical setting in Mexico.


REFERENCES

  1. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels, Belgium: IDF Executive Office; 2015. Disponible en: http://www.diabetesatlas. org. Accessed March 20, 2017.

  2. Hernandez-Avila M, Gutierrez JP. Diabetes mellitus: la urgencia de reforzar la respuesta en políticas públicas para su prevención y control. Mexico: Instituto Nacional de Salud Pública; 2012.

  3. Prado-Serrano A, Guido-Jimenez MA, Camas-Benitez JT. Prevalencia de retinopatía diabética en población mexicana. Rev Mex Oftalmol. 2009; 83(5):261-266.

  4. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464-74.

  5. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4(6):151-69.

  6. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-405.

  7. Mitchell P, Massin P, Bressler S, Coon CD, Petrillo J, Ferreira A, et al. Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study. Curr Med Res Opin. 2015;31(11):1967-75.

  8. Prünte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100(6):787-95.

  9. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gerry W, Thomas Gross, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375:2293-7.

  10. Bertelmann T, Feltgen N, Scheffler M, Hufenbach U, Wiedon A, Wilhelm H, et al. Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study. Health Qual Life Outcomes. 2016;14(1):132.

  11. Ghanchi F, Hazel CA. South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience. Eye Lond Engl. 2016;30(1):133-8.

  12. Granström T, Forsman H, Lindholm Olinder A, Gkretsis D, Eriksson JW, Granstam E, et al. Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting. Diabetes Res Clin Pract. 2016;121:157-65.

  13. Hernández-Salazar L, Aranda-Serna S, Orozco-Gómez LP, Azuara- Azuara C, Bracamontes-Barragán J, Collado-Solórzano A, et al. Guía para el diagnóstico y el tratamiento del edema macular diabético en derechohabientes del ISSSTE. Rev Esp Med Quir. 2015;20:321-7.

  14. Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond). 2014;28(5):510-20.

  15. Ip MS, Zhang J, Ehrlich JS. The clinical importance of changes in diabetic retinopathy severity score. Ophthalmology. 2017;124(5):596-603.

  16. Mathur R, Bhaskaran K, Edwards E, Lee H, Chaturvedi N, Smeeth L, et al. population trends in the Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study in the Clinical Practice Research Datalink 2004–2014. BMJ Open. 2017;7(2):e014444.

  17. Dugel PU, Hillenkamp J, Sivaprasad S, Vögeler J, Mousseau M-C, Wenzel A, et al. Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials. Clin Ophthalmol Auckl NZ. 2016;10:1103-10.




2020     |     www.medigraphic.com